Department of Pulmonology and Immunology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania ; Mykolas Romeris University, Vilnius, Lithuania.
Arch Med Sci. 2012 Dec 20;8(6):1053-8. doi: 10.5114/aoms.2012.32414. Epub 2012 Dec 19.
Chronic obstructive pulmonary disease (COPD) has been recently defined as a systemic pulmonary inflammatory disease, and congenital α1 antitrypsin deficiency is one of the well-established genetic risk factors for chronic obstructive pulmonary disease. The aim of our study was to evaluate the possible associations of α1 antitrypsin with inflammatory markers - CRP, sCD14, TNF-α, sTNFR-1, and sTNFR-2 - in patients with COPD with different α1 antitrypsin genotypes.
Serum biomarkers from patients (n = 355) with COPD, defined according to the GOLD criteria, were analyzed using commercial ELISA kits; α1 antitrypsin concentrations were determined by nephelometry, and α1 antitrypsin phenotyping was carried out by means of isoelectric focusing.
No significant differences in CRP, TNF-α, sTNFR-1, sTNFR-2, and sCD14 levels were found comparing COPD patients with different genotypes. In patients without α1 antitrypsin deficiency (PI*MM), a significant negative correlation between lung function (FEV(1)) and serum α1 antitrypsin (r = -0.522, p = 0.03) and CRP concentration (r = -0.590, p = 0.011) was detected. The level of α1 antitrypsin positively correlated with: a) CRP concentration (r = 0.671, p = 0.005), b) sCD14 (r = 0.510, p = 0.008) and c) sTNFR-1 (r = 0.567, p = 0.007).
In patients without α1 antitrypsin deficiency, the positive association of α1 antitrypsin concentration with CRP, sCD14, and sTNFR-1 and the negative association with FEV(1) show the importance of α1 antitrypsin as a marker of systemic inflammation.
慢性阻塞性肺疾病（COPD）最近被定义为一种系统性肺部炎症性疾病，先天性α1 抗胰蛋白酶缺乏症是慢性阻塞性肺疾病的公认遗传危险因素之一。我们的研究目的是评估 α1 抗胰蛋白酶与炎症标志物——C 反应蛋白（CRP）、可溶性 CD14（sCD14）、肿瘤坏死因子-α（TNF-α）、可溶性肿瘤坏死因子受体-1（sTNFR-1）和可溶性肿瘤坏死因子受体-2（sTNFR-2）——在不同 α1 抗胰蛋白酶基因型 COPD 患者中的可能相关性。
使用商业 ELISA 试剂盒分析了根据 GOLD 标准定义的 COPD 患者（n=355）的血清生物标志物；通过散射比浊法测定 α1 抗胰蛋白酶浓度，通过等电聚焦法进行 α1 抗胰蛋白酶表型分析。
比较不同基因型的 COPD 患者，发现 CRP、TNF-α、sTNFR-1、sTNFR-2 和 sCD14 水平无显著差异。在无α1 抗胰蛋白酶缺乏症（PI*MM）的患者中，肺功能（FEV1）与血清α1 抗胰蛋白酶（r=-0.522，p=0.03）和 CRP 浓度（r=-0.590，p=0.011）之间存在显著负相关。α1 抗胰蛋白酶水平与以下指标呈正相关：a）CRP 浓度（r=0.671，p=0.005），b）sCD14（r=0.510，p=0.008）和 c）sTNFR-1（r=0.567，p=0.007）。
在无α1 抗胰蛋白酶缺乏症的患者中，α1 抗胰蛋白酶浓度与 CRP、sCD14 和 sTNFR-1 呈正相关，与 FEV1 呈负相关，表明 α1 抗胰蛋白酶作为系统性炎症标志物的重要性。
